

*Sub-D3* 3 wherein said second vaccine antigen has an adjuvant effect on HBsAg, and wherein said first and second vaccine antigens are each present up to about 1 mg.

16. (Amended) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is the nucleocapsid antigen of Hepatitis B virus.
17. (Amended) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is the nucleocapsid antigen of Human Papilloma-virus.
18. (Amended) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is the nucleocapsid antigen of Hepatitis C virus.
19. (Twice amended) The vaccine formulation according to claim 15, wherein the second vaccine antigen comprises a single antigen or a mixture of different antigens that are immuno-enhanced by HBsAg.  
*C3* 3
20. The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for administration as a solid, liquid or spray.
21. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for nasal administration.
22. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis B virus (HBV) infection.

*Sub B3*

23. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis B virus (HBV) infection.

24. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis C virus (HCV) infection.

25. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a preventive vaccine against Human Papilloma virus (HPV) infection.

*C3*

26. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis C virus (HCV) infection.

27. (Amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Human Papilloma virus (HPV) infection.

---

31. (Amended) The vaccine formulation according to claim 19, wherein the second vaccine antigen comprises the core antigen of Hepatitis B virus.

*C4*

32. (Amended) The vaccine formulation according to claim 19, wherein the second vaccine antigen comprises the nucleocapsid antigen of Hepatitis C virus.

*Sub A*

---

*C5 sub D3*  
33. (Amended) The vaccine formulation according to claim 19, wherein the second vaccine

antigen comprises the nucleocapsid antigen of Human Papilloma-virus.

*sub D3*  
34. (New) The vaccine formulation according to claim 15, wherein said second vaccine

antigen has an adjuvant effect on said surface antigen.

*C6*  
35. (New) The vaccine formulation according to claim 15, further comprising a preservative.

36. (New) The vaccine formulation according to claim 15, further comprising a stabilizer.

37. (New) The vaccine formulation according to claim 15, further comprising a third vaccine antigen.